FGF-9 is an autocrine and paracrine prostatic growth factor expressed by prostatic stromal cells. FGF-9 induces osteoblast proliferation and new bone formation in a bone organ assay. FGF-9 is produced by many prostate cancer cells and contributes to prostate cancer-induced new bone formation. It also may participate in the osteoblastic progression of prostate cancer in bone. It is also an autocrine and/or paracrine neurotrophic factor that promotes the survival of motoneurons and upregulates choline acetyl-transferase activity. FGF-9 enhances survival of AChE-positive neurons and increases their mean soma size. It also up-regulates their choline acetyltransferase activity as potently as NGF and the effect is greater than that elicited by bFGF, CNTF, or GDNF. FGF-9 acts as a survival factor for neurons but does not promote neurite outgrowth. FGF-9 has been shown to mediate its effects by binding to FGF receptors. It efficiently activates the FGFR2c splice form of FGFR2 and the FGFR3b and FGFR3c splice isoforms of FGFR3.
Aliases- FGF-9, Glia-activating factor, GAF, Heparin-binding growth factor 9, HBGF-9
- Recombinant Human Fibroblast Growth Factor 9 (FGF9)
Formulation- Recombinant FGF-9 was lyophilized from a 0.2 µm filtered PBS solution.
Endotoxin Level- <1.0 EU/µg of recombinant protein as determined by the LAL method.
Storage Condition- The lyophilized protein is stable for at least one year from date of receipt at -70°C. Upon reconstitution, this cytokine can be stored in working aliquots at +2° to +8°C for one month, or at -20°C for six months, with a carrier protein without detectable loss of activity. Avoid repeated freeze/thaw cycles.